Go to the list of all blogs
Rick Johnson's Avatar
published in Blogs
Nov 18, 2026
TickeronGET DAILY SIGNALS
Why Is Quantum-Si Incorporated (QSI) Stock Up +14.85% Today?

Why Is Quantum-Si Incorporated (QSI) Stock Up +14.85% Today?

Key Takeaways

  • Shares of QSI climbed 14.85% to $1.16 in late-morning trading, up from the prior session's close of $1.01.
  • The primary catalyst was a company announcement that it has demonstrated detection of all 20 naturally occurring amino acids in its Proteus development program, reaching a year-end 2026 goal ahead of schedule.
  • Secondary drivers include follow-through buying after two prior amino-acid milestones, a rebound from a roughly 42% pullback off October highs, and light short interest that amplifies upside moves in a thin tape.
  • The advance was company-specific: the release carried no read-through for protein-sequencing peers or the broader life-sciences tools group.
  • Even after the pop, the stock trades below its 20-session average near $1.32, with the Proteus commercial launch still targeted for the second quarter of 2027.
  • News Significance Score: 38/100 - A genuine but pre-commercial technical milestone paired with a move roughly 2.3 times the stock's typical daily swing.
  • Traders are watching for the developmental sequencing kit built around 20-amino-acid detection, further Proteus performance data, and any change to the Q2 2027 launch timeline.
  • Investors can find deeper detail on Price Targets, Earnings, and Forecast pages dedicated to the stock.
  • For systematic, rules-based exposure to names like this one, explore Trending AI Robots.

Opening Summary

QSI is Quantum-Si Incorporated, a Branford, Connecticut-based proteomics company developing benchtop, single-molecule protein-sequencing instruments, consumables and analysis software sold under its Platinum and Proteus brands. The stock is up 14.85% on the session, trading at $1.16 against a prior close of $1.01, with the direction firmly to the upside. The immediate reason is unambiguous: before the opening bell, Quantum-Si said it had detected all 20 standard amino acids in its Proteus development program, a technical benchmark the company had targeted for the end of 2026. The stock gapped higher at the open, touched $1.21, and has held most of the gain.

The All-20 Amino Acid Milestone

Proteins are built from a 20-letter alphabet of amino acids, and reading protein sequence requires distinguishing every one of them — the equivalent of calling all four nucleotide bases in DNA sequencing. Quantum-Si said it has now demonstrated detection of the complete set at the single-molecule level inside its Proteus development program, four months ahead of its own deadline and after disclosing 18- and then 19-amino-acid coverage at earlier checkpoints in September and October.

Management framed the result as a platform-defining proof of chemistry rather than a commercial event. Chief Executive Jeff Hawkins described it as a foundational benchmark that could support reference-free protein identification and broader analysis of proteoforms, sequence variants and post-translational modifications. For a development-stage company whose trailing revenue is barely above $1 million, that is precisely the kind of de-risking signal investors have been paying for.

The context matters, however. Quantum-Si is now working to fold 20-amino-acid detection into a developmental sequencing kit for Proteus instruments, and commercialization of the platform itself has already slipped to the second quarter of 2027 from an earlier end-of-2026 target, with management citing instrument reproducibility, manufacturing yields and component supply. Today's news validates the science, not the launch schedule or the revenue line.

Positioning and Rebound Dynamics

The rally also has a mechanical component. QSI had fallen from a close of $1.75 on October 29 to $1.01 on November 17, a decline of roughly 42% that left the shares below their 20-session average and back near levels that previously triggered a Nasdaq minimum-bid issue. With short interest near 12.7 million shares as of the latest settlement data and float that trades lightly relative to larger peers, a fundamentally positive headline tends to produce an outsized percentage response. The pattern of double-digit single-session gains on milestone news is well established here — the October 8 disclosure of 19-amino-acid detection preceded a 25% jump.

Market Context and Trading Activity

Activity is clearly elevated. Roughly 3.2 million shares changed hands in the first 70 minutes of the session, close to half the average full-day volume of about 6.7 million shares, on a stock with a market value of roughly $255 million. The move opened with a gap and has held in a $1.15–$1.21 range since, which suggests a mix of new buyers and profit-taking rather than a single algorithmic spike.

The catalyst was company-specific, and the tape reflected that: no peer or sector-wide news accompanied the release, and the broad direction of small-cap life-sciences tools names did not drive the gain. Technically, the stock reclaimed the $1.10 area it lost in mid-November but remains below its 20-session average of roughly $1.32, leaving the mid-October breakdown zone as the next meaningful resistance reference.

News Significance Score

The score runs from 0 to 100, where 0 means no meaningful news and a price move that is routine for the stock, and 100 means transformative news combined with an extreme, rare move. Quantum-Si earns 38 out of 100. The verified news was substantive but developmental — a technical milestone in a program whose commercial launch is still more than a year out, with no revenue or guidance impact — so it sits in the moderate-to-major band rather than the transformative one. The price move, at roughly 2.3 times the stock's typical daily swing of about 6.5%, was notable but not extraordinary: moves of similar or greater magnitude have occurred six times in the last 60 sessions. Strong-ish news and a moderately unusual move together produce the mid-30s score.

What Comes Next for QSI

The next hard checkpoint is execution on the developmental kit, with management promising additional Proteus performance data as that work progresses. Investors will also press for clarity on the Q2 2027 launch timeline, manufacturing yields and the pricing strategy for a platform that must displace entrenched mass-spectrometry workflows.

On the financial side, the company reports fourth-quarter and full-year results in the first quarter of 2027; the third quarter brought a narrower-than-expected loss but revenue of just $0.21 million, well short of expectations. Cash of roughly $103 million gives runway, but dilution risk remains a structural feature of the story. Analyst coverage is thin, with a consensus leaning constructive and a wide spread of targets. Risks include further launch delays, competitive pressure from larger tools makers and other protein-sequencing entrants, and the volatility inherent to a sub-$2 stock with a small float.

Trending AI Robots

Tickeron's Trending AI Robots page curates the strongest-performing automated strategies under current market conditions from a library of hundreds of AI trading bots spanning thousands of tickers. Bots differ widely by strategy logic, holding period, risk profile, performance metrics and the symbols they trade, so the featured list changes as market conditions evolve. It is a practical starting point for traders who want to see which approaches are working right now rather than sifting through the full catalogue. Review the current leaders and compare them against your own process.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: QSI

QSI sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for QSI moved above the 200-day moving average on October 23, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +17.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where QSI advanced for three days, in 160 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

The Aroon Indicator entered an Uptrend today. In 100 of 122 cases where QSI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.

Bearish Trend Analysis

The 10-day RSI Indicator for QSI moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 25 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on QSI as a result. In 78 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.

The Moving Average Convergence Divergence Histogram (MACD) for QSI turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 36 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.

QSI moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where QSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

QSI broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. QSI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.616) is normal, around the industry mean (4.142). P/E Ratio (-2.891) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (100.000) is also within normal values, averaging (40.124).

The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -9%. For the same Industry, the average monthly price growth was -9%, and the average quarterly price growth was -14%. POAS experienced the highest price growth at 172%, while LFWD experienced the biggest fall at -46%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -44%. For the same stocks of the Industry, the average monthly volume growth was -3% and the average quarterly volume growth was -49%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 62
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 14 (-100 ... +100)
Real Time Patterns 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry MedicalNursingServices

Industry
N/A
Address
29 Business Park Drive
Phone
+1 866 688-7374
Employees
138
Web
https://www.quantum-si.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.